scholarly journals Effect of cytomegalovirus infection on moderate and severe ulcerative colitis

2021 ◽  
Vol 20 (3) ◽  
pp. 28-34
Author(s):  
T. L. Alexandrov ◽  
B. A. Nanaeva ◽  
T. A. Baranova ◽  
I. A. Tishaeva ◽  
D. V. Podolskaya ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Antiviral Therapy ◽  
Randomized Trials ◽  
Steroid Resistance ◽  
Cmv Infection ◽  
Chain Reaction ◽  
Virus Eradication ◽  
Previous Therapy ◽  
Single Center Study ◽  
Polymerase Chain

AIM: to evaluate the effect of cytomegalovirus (CMV) infection on the course of moderate and severe flare ups of ulcerative colitis (UC).PATIENTS AND METHODS: a prospective cohort single-center study was done in September 2018 — December 2020. The study included patients with moderate and severe flare ups of UC. All patients underwent colonoscopy with biopsy to quantify CMV DNA by polymerase chain reaction (PCR). Subsequently, the patients were divided into subgroups: with the presence of CMV (CMV+) and its absence (CMV–). In the CMV+ subgroup, antiviral therapy was carried out with an assessment of virological, clinical and endoscopic results on the 19th day of therapy, one month after its completion and after 6 months. In the CMV– subgroup these results were evaluated after 6 months only.RESULTS: the study included 126 patients. CMV was detected in 51 (40.5%). At the same time, its presence was not influenced by gender, age, or previous therapy. Laboratory indicators in both subgroups were comparable, as well as the severity of UC. A significant increase in the risk of developing steroid resistance was revealed in CMV+ patients with severe UC attack (OR 1.33, 95% CI: 1.059–19.4). The effectiveness of antiviral therapy was 60.8%. All patients who did not respond to antiviral therapy underwent surgery. At the same time, among patients in whom antiviral therapy was effective (virus eradication was achieved), there was no need for surgery.CONCLUSION: CMV infection significantly increases the likelihood of developing steroid resistance in patients with severe flare up of UC, while all patients who responded to antiviral therapy did not require surgery. Further multicenter randomized trials are needed.

scholarly journals Effect of cytomegalovirus infection on moderate and severe ulcerative colitis

2021 ◽  
Vol 20 (3) ◽  
pp. 28-34
Author(s):  
T. L. Alexandrov ◽  
B. A. Nanaeva ◽  
T. A. Baranova ◽  
I. A. Tishaeva ◽  
D. V. Podolskaya ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Antiviral Therapy ◽  
Randomized Trials ◽  
Steroid Resistance ◽  
Cmv Infection ◽  
Chain Reaction ◽  
Virus Eradication ◽  
Previous Therapy ◽  
Single Center Study ◽  
Polymerase Chain

AIM: to evaluate the effect of cytomegalovirus (CMV) infection on the course of moderate and severe flare ups of ulcerative colitis (UC).PATIENTS AND METHODS: a prospective cohort single-center study was done in September 2018 — December 2020. The study included patients with moderate and severe flare ups of UC. All patients underwent colonoscopy with biopsy to quantify CMV DNA by polymerase chain reaction (PCR). Subsequently, the patients were divided into subgroups: with the presence of CMV (CMV+) and its absence (CMV–). In the CMV+ subgroup, antiviral therapy was carried out with an assessment of virological, clinical and endoscopic results on the 19th day of therapy, one month after its completion and after 6 months. In the CMV– subgroup these results were evaluated after 6 months only.RESULTS: the study included 126 patients. CMV was detected in 51 (40.5%). At the same time, its presence was not influenced by gender, age, or previous therapy. Laboratory indicators in both subgroups were comparable, as well as the severity of UC. A significant increase in the risk of developing steroid resistance was revealed in CMV+ patients with severe UC attack (OR 1.33, 95% CI: 1.059–19.4). The effectiveness of antiviral therapy was 60.8%. All patients who did not respond to antiviral therapy underwent surgery. At the same time, among patients in whom antiviral therapy was effective (virus eradication was achieved), there was no need for surgery.CONCLUSION: CMV infection significantly increases the likelihood of developing steroid resistance in patients with severe flare up of UC, while all patients who responded to antiviral therapy did not require surgery. Further multicenter randomized trials are needed.

scholarly journals Anosmia as a Screening Tool for COVID-19 Infection: A Prospective Cohort Study

2021 ◽  
pp. 1-6
Author(s):  
Esra AlHamadani ◽  
Sania Zia ◽  
Ali AlRahma ◽  
Firas AlNajjar
Keyword(s):  
Odds Ratio ◽  
Screening Tool ◽  
Index Finger ◽  
Upper Respiratory Tract ◽  
Chain Reaction ◽  
The Public ◽  
Single Center Study ◽  
Upper Respiratory ◽  
Polymerase Chain ◽  
Low Sensitivity

<b><i>Objectives:</i></b> Several studies promoted anosmia as a possible isolated symptom for coronavirus disease 2019 (COVID-19). No studies used feasible methods of smell testing that the public would use to address the accuracy of these claims. <b><i>Methods:</i></b> This is a single-center study conducted between April 2020 and June 2020. The sense of smell was tested in vitally stable suspected COVID-19 patients with no/mild upper respiratory tract infection symptoms prior to nasopharyngeal swabbing for reverse-transcriptase polymerase chain reaction. Patients were instructed to close their eyes. Each nostril was tested separately while the other was blocked with the patient’s index finger. Patients inhaled from 2 concealed vials (coffee and strawberry essence) consecutively, kept within 30 cm of the nostril for 60 s. Patients who could not identify both odors with both nostrils were recorded as “anosmia.” <b><i>Results:</i></b> Out of 346 eligible subjects, 43 had anosmia of which 26 (60%) tested COVID-19 positive. χ<sup>2</sup> test showed a <i>p</i> value &#x3c;0.001. The test showed a sensitivity of 30% (95% confidence interval [CI] 21%, 41%) and specificity 94% (95% CI 90%, 96%). Logistic regression revealed an odds ratio of 5.9 (95% CI 3.0, 12) <i>p</i> value &#x3c;0.001. <b><i>Conclusion:</i></b> Given the low sensitivity (30%) of this method in detecting COVID-19 infection, we conclude that this method is not a useful screening tool for COVID-19 infection. The moderate negative predictive value (80%) is nongeneralizable.

scholarly journals PTU-083 Use Of Polymerase Chain Reaction To Detect Mucosal Cytomegalovirus Infection In Patients With Acute Ulcerative Colitis

Gut ◽  
2014 ◽  
Vol 63 (Suppl 1) ◽  
pp. A75.2-A76 ◽  
Author(s):  
GSZ Tun ◽  
A Wright ◽  
K Robinson ◽  
R Sidhu ◽  
A Hopper ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Polymerase Chain Reaction ◽  
Cytomegalovirus Infection ◽  
Chain Reaction ◽  
Polymerase Chain

scholarly journals An Unusual Presentation of Cytomegalovirus Infection: Generalized Edema

2019 ◽  
Vol 29 (1) ◽  
pp. 94-96 ◽  
Author(s):  
Ceyda Tuna Kirsaclioglu ◽  
Gulin Hizal ◽  
Esra Karakus ◽  
Tulin Revide Sayli
Keyword(s):  
Cytomegalovirus Infection ◽  
Clinical Presentation ◽  
Gastrointestinal Symptoms ◽  
Related Protein ◽  
Cmv Infection ◽  
Protein Loss ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Gastrointestinal Protein Loss ◽  
Protein Losing Gastropathy

Objective: Cytomegalovirus (CMV) infection may rarely lead to protein-losing gastropathy that presents with nausea, vomiting, abdominal pain, and edema in immunocompetent children, but extremely rarely with only generalized edema. Clinical Presentation and Intervention: A previously healthy 5-year-old boy presented with generalized edema without any other symptoms. He had hypoalbuminemia but no proteinuria. He was evaluated for gastrointestinal protein loss, and hypertrophic gastropathy was revealed on esophagogastroduodenoscopy. Meanwhile, CMV infection was detected by serologic tests and polymerase chain reaction in the blood. He recovered spontaneously within a week. Conclusion: CMV-related protein-losing gastropathy may present with generalized edema without any gastrointestinal symptoms.

Sign in / Sign up

Export Citation Format

Share Document